We work in disease areas with some of the greatest unmet need. We work relentlessly, knowing that bold new possibilities await discovery. As a leading global biotechnology company, we work toward those once-in-a-lifetime moments that could become a historic point in our pursuit of innovative treatments.
Science & Innovation
Disease Areas
The potential to transform the lives of patients drives us at Biogen
Alzheimer’s disease and dementia
Our world-class neurology research and development organization is pushing toward novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease.
Learn more
Amyotrophic lateral sclerosis (ALS)
For over a decade, Biogen has been committed to advancing ALS research to provide a deeper understanding of all forms of this devastating disease, which currently impacts an estimated 352,000 people worldwide.1,2*
Learn more
Friedreich Ataxia
Biogen is proud to leverage our expertise in rare diseases to build on the outstanding work Reata has done to launch the first and only U.S. Food and Drug Administration (FDA) and European Commission (EC) approved treatment for FA in adults and adolescents aged 16 years and older. Biogen will continue our commitment and capabilities to help bring this treatment to more patients living with this devastating disease.
Learn more
Multiple sclerosis (MS)
Biogen has pioneered the development of multiple sclerosis treatments for more than 25 years. We continue to innovate to advance MS treatment and improve outcomes for patients. Our research is focused on potentially transformative therapies, including the potential repair of the damage caused by MS. Our ongoing research into neurodegeneration and nerve repair will help pioneer new therapeutic solutions that may bring us closer to a cure for MS.
Learn more
Spinal muscular atrophy (SMA)
Biogen is dedicated to enhancing the lives of those with SMA and their families through ongoing research, removing barriers to access and providing support programs. In December 2017, Biogen launched a new collaboration with Ionis to identify new therapeutic options — specifically, new antisense oligonucleotide (ASO) candidates, which are designed to treat SMA — for individuals afflicted with the debilitating disease.
Learn more
Breaking new ground with science
With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
References
- Xu 2020. Reference: Xu L, Liu T, Liu L, Yao X, Chen L, Fan D, Zhan S, Wang S. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020 Apr;267(4):944-953
- United Nations, World population prospects: The 2010 revision (2022). New York.
* calculated based on prevalence estimates and applied to the global population